SONET生物治疗学第一阶段试验显示SON-1010是安全的,可能有助于治疗高级肿瘤。 Sonnet BioTherapeutics' Phase 1 trial shows SON-1010 is safe and may help treat advanced tumors.

Sonnet生物治疗学报告说,其第一阶段对SON-1010进行治疗先进固态肿瘤的试验取得了积极的安全结果。 Sonnet BioTherapeutics reported positive safety results from its Phase 1 trial of SON-1010 for treating advanced solid tumors. 在最高剂量为1,200纳克/千克时,该药物未显示出重大的副作用。 The drug showed no major side effects at the highest dose of 1200 ng/kg. 在试验期间,48%的病人患有稳定疾病,其中一人的肿瘤体积明显缩小。 In the trial, 48% of patients had stable disease, with one showing a significant reduction in tumor size. 该公司看到了将SON-1010与其他癌症治疗相结合的潜力。 The company sees potential for combining SON-1010 with other cancer treatments.